This combination therapy induces apoptosis in CRC cells via caspase-3 and PARP activation while also affecting key signaling pathways such as PI3K/Akt, known for regulating cancer cell survival and proliferation [80]. This evidence concerns the gene CASP3 and colorectal carcinoma.